Arrowstreet Capital, Limited Partnership Neu Base Therapeutics, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

  • $121 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 14, 2021
SELL
$6.92 - $12.36 $157,084 - $280,572
-22,700 Closed
0 $0
Q4 2020

Feb 12, 2021
SELL
$6.92 - $9.25 $221,440 - $296,000
-32,000 Reduced 58.5%
22,700 $159,000
Q3 2020

Nov 12, 2020
BUY
$7.25 - $9.71 $396,575 - $531,137
54,700 New
54,700 $415,000

About NeuBase Therapeutics, Inc.

NBSE Quotes by TradingView
  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track This Portfolio

Track Arrowstreet Capital, Limited Partnership Portfolio

Follow Arrowstreet Capital, Limited Partnership and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email